## **Makers Laboratories Limited**

Regd. Office : 54D, Kandivali Industrial Estate, Kandivali (W), Mumbai 400 067

CIN : L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30,

2017

		· . 4	(Rs in Lacs)
ir. No.	Particulars	Quarter Ended	
	•	30.6.2017	30.6.2016
1	Revenue form operations	1,140.19	1,291.53
П	Other Income	25.02	10.94
<u>{</u> ]]	Total income (I+II)	1,165.21	1,302.47
IV	Expenses		· · ·
	a) Cost of materials consumed	394.44	505.11
	b) Purchases of stock-in-trade	496.43	533.20
	c) Changes in inventories of finished goods,	(208.00)	(334.34)
	work-in-progress and stock-in-trade		
	d) Employee benefits expense	178.36	169.55
	e) Finance Cost	7.68	6.60
	f) Depreciation and amortisation expense	38.78	24.48
	g) Other expenses	270.98	287.26
	Total Expenses (IV)	1,178.67	1,191.86
V	Profit/(Loss) before exceptional items and tax (III-IV)	(13.46)	110.61
VI	Exceptional items : Profit on sale of Dombivali Manufacturing Unit		79.07
VII	Profit/(Loss) before tax (V+VI)	(13.46)	189.68
VIII	Tax Expense		
	Current	-	47.03
	Deferred	2.12	16.42
IX	Net Profit/(Loss) after tax (VII-VIII)	(15.58)	126.23
х	Other Comprehensive Income		
	a) items that will not be reclassified to profit & loss	(5.51)	(3.62)
	- Tax expenses thereon	-	1.20
	b) items that will be classified to profit & loss		. –
	- Tax expenses thereon	-	-
XI	Total Comprehensive Income after tax (IX + X)	(21.09)	121.41
XII	Paid-up equity share capital (Face value of Rs 10/- each)	491.70	491.70
XIII	Earnings per share (of Rs.10/- each) - Not annualised :		
	Basic & Diluted	(0.32)	2.57

Notes:

- 1 The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 10, 2017.
- 2 The Auditors of the Company have carried out the limited review of the financial results only for the quarter ended June 30, 2017. The Ind AS compliant financial results of the corresponding quarter ended June 30, 2016 have been stated in terms of SEBI Circular CIR/CFD/FAC/62/2016 dated July 5, 2016. The financial results relating to the quarter ended June 30, 2016 under Ind AS have not been subjected to limited review by the statutory auditors of the Company. However, the management has exercised necessary due diligence and ensured that the financial results provide a true and fair view of its affairs in accordance with the Companies (Indian Accounting Standards) Rules 2015.
- 3 The Reconciliation of Net profit as per Ind AS and previous GAAP for the quarter ended June 30, 2016 is as under.

	(R:	s in Lacs)
Particulars	Profit Reconciliation Quarter ended 30.6.2016	
Net profit as per previous GAAP		108.27
Expected credit loss reversed	23.95	
Employee Benefits Actuarial gain/(loss) adjustments net of tax	4.82	
Impact on revenue due to application of Ind AS - 18	, 3.00	
Deferred Tax	(13.81)	17.96
Net profit as per Ind AS		126.23

- 4 The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rule, 2016.
- 5 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'.
- 6 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

ORAT

MUME

By Order of the Board For Makers Laboratories Lin

and

(Pulnima Jain Whole)Time Director

(DIN 00937041)